Adaptive immunity: an emerging player in the progression of NAFLD

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249

Mechanisms of NAFLD development and therapeutic strategies

Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435

Nonalcoholic Fatty Liver Disease

Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046

Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression

Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764

Immunology in the liver — from homeostasis to disease

Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077

The immunology of hepatocellular carcinoma

Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076

Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice

Rostama, B., Beauchemin, M., Bouchard, C., Bernier, E., Vary, C., May, M. A., & Houseknecht, K. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249362 · Cited by 27

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update

Deng, C., Lo, T.-H., Chan, K.-Y., Li, X., Wu, M., Xiang, Z., & Wong, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012376 · Cited by 29

From “Traditional” to “Trained” Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Romeo, M., Silvestrin, A., Senese, G., Nardo, F. D., Napolitano, C., Vaia, P., Coppola, A., Federico, P., Dallio, M., & Federico, A. (2025) · Biomedicines · doi:10.3390/biomedicines13082004 · Cited by 29

The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor

Zhang, X., Li, R., Chen, Y., Dai, Y., Chen, L., Qin, L., Cheng, X., & Lu, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.598836 · Cited by 26

A Mineralocorticoid Receptor Deficiency in Myeloid Cells Reduces Liver Steatosis by Impairing Activation of CD8+ T Cells in a Nonalcoholic Steatohepatitis Mouse Model

Muñoz‐Durango, N., Arrese, M. A., Hernández, A., Jara, E. L., Kalergis, A. M., & Cabrera, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563434 · Cited by 26

Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis

Huang, H., Fan, S., Zhou, X., Liu, Y., Xiao, L., Liao, L., Huang, J. L., Shi, C., Liang, Y., Fu, R., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00725-1 · Cited by 26

Peripheral immune cells in NAFLD patients: A spyhole to disease progression

Lin, S., & Fan, J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103768 · Cited by 26

Inflammatory processes involved in NASH-related hepatocellular carcinoma

Cannito, S., Dianzani, U., Parola, M., Albano, E., & Sutti, S. (2023) · Bioscience Reports · doi:10.1042/bsr20221271 · Cited by 29

Comparison of hepatic gene expression profiles between three mouse models of Nonalcoholic Fatty Liver Disease

Xiang, L., Jiao, Y., Qian, Y., Li, Y., Mao, F., & Lü, Y. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.02.008 · Cited by 25

Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease

Chen, S., Guo, H., Xie, M., Zhou, C., & Zheng, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107609 · Cited by 25

High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients

Liu, D.-F., Yuan, X.-Y., Gao, F., Zhao, B.-N., Ding, L., Huan, M.-J., Liu, C., & Jiang, L.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899930 · Cited by 25

Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis

Sangineto, M., Ciarnelli, M., Colangelo, T., Moola, A., Bukke, V. N., Duda, L., Villani, R., Romano, A. D., Giandomenico, S., Kanwal, H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101564 · Cited by 26

The Translational Bridge between Inflammation and Hepatocarcinogenesis

Gufler, S., Seeboeck, R., Schatz, C., & Haybaeck, J. (2022) · Cells · doi:10.3390/cells11030533 · Cited by 26

Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease

Zhou, L., Shen, H., Li, X., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951406 · Cited by 27

A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice

Zheng, S., Yang, W., Yao, D., Tang, S., Hou, J., & Chang, X. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2108894 · Cited by 23

Immunometabolic Interactions in Obesity: Implications for Therapeutic Strategies

Fei, Q., Huang, J., He, Y., Zhang, Y., Zhang, X., Wang, J., & Fu, Q. (2025) · Biomedicines · doi:10.3390/biomedicines13061429 · Cited by 28

Oxysterol 7-α Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality

Evangelakos, I., Schwinge, D., Worthmann, A., John, C., Roeder, N., Pertzborn, P., Behrens, J., Schramm, C., Scheja, L., & Heeren, J. (2021) · Cells · doi:10.3390/cells10102656 · Cited by 23

The Critical and Diverse Roles of CD4–CD8– Double Negative T Cells in Nonalcoholic Fatty Liver Disease

Li, C., Du, X., Shen, Z., Wei, Y., Wang, Y., Han, X., Jin, H., Zhang, C., Li, M., Zhang, Z., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.019 · Cited by 23

The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis

Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03595-1 · Cited by 24

Macrophage metabolism in nonalcoholic fatty liver disease

Zhang, W., & Lang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257596 · Cited by 28

The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models

Aki, D., Hayakawa, T., Srirat, T., Shichino, S., Ito, M., Saitoh, S.-I., Mise-Omata, S., & Yoshimura, A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175305 · Cited by 22

Advancements in MAFLD Modeling with Human Cell and Organoid Models

Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

Rabiu, L., Zhang, P., Afolabi, L. O., Saliu, M. A., Dabai, S. M., Suleiman, R. B., Gidado, K. I., Ige, M. A., Ibrahim, A., Zhang, G., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02157-0 · Cited by 24

Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD)

Darmadi, D., & Ruslie, R. H. (2020) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2020-0029 · Cited by 22

Modulation of Oxidative Stress-Induced Senescence during Non-Alcoholic Fatty Liver Disease

Pedroza-Díaz, J., Arroyave-Ospina, J. C., Salas, S. S., & Moshage, H. J. (2022) · Antioxidants · doi:10.3390/antiox11050975 · Cited by 27

The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease

Munteanu, C., & Schwartz, B. (2023) · Antioxidants · doi:10.3390/antiox12040903 · Cited by 26

Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling

Yang, J., He, J., Feng, Y., & Xiang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166440 · Cited by 25

Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications

Guo, Z., Wu, Q., Xie, P., Wang, J., & Lv, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336493 · Cited by 23

Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum

Xie, C., Yuan, Y., Wang, Y., Qi, C., Wang, W., An, C., Aikepaer, A., Zhang, Y., Zhang, G., Feng, X., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00673-5 · Cited by 28

Bacterial antigen translocation and age as BMI‐independent contributing factors on systemic inflammation in NAFLD patients

Gómez‐Hurtado, I., Gallego‐Durán, R., Zapater, P., Ampuero, J., Aller, R., Crespo, J., Arias‐Loste, M., García‐Monzón, C., Bellot, P., González‐Rodríguez, Á., et al. (2020) · Liver International · doi:10.1111/liv.14571 · Cited by 22

Systemic and adipose tissue inflammation in NASH: correlations with histopathological aspects

Micu, E. S., Amzolini, A., Abu-Alhija, A. B., Forțofoiu, M., Vladu, I., Clenciu, D., Mitrea, A., Mogoantă, S., Crișan, A., Predescu, O., et al. (2021) · Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie · doi:10.47162/rjme.62.2.17 · Cited by 19

Roles of Cellular Neighborhoods in Hepatocellular Carcinoma Pathogenesis

Ma, L., Li, C., & Wang, X. W. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023520 · Cited by 19

LY6D is crucial for lipid accumulation and inflammation in nonalcoholic fatty liver disease

Lee, J., Kim, H., Kang, Y.-W., Kim, Y., Park, M.-Y., Song, J., Jo, Y., Dao, T., Ryu, D., Lee, J., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01033-w · Cited by 20

Role of the immune system in liver transplantation and its implications for therapeutic interventions

Chen, G., Hu, X., Huang, Y., Xiang, X., Pan, S., Chen, R., & Xu, X. (2023) · MedComm · doi:10.1002/mco2.444 · Cited by 22

From MASLD to HCC: What's in the middle?

Provera, A., Vecchio, C., Sheferaw, A. N., Stoppa, I., Pantham, D., Dianzani, U., & Sutti, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35338 · Cited by 26

The regulatory function of mixed lineage kinase 3 in tumor and host immunity

Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107704 · Cited by 19

Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells

Koda, Y., Nakamoto, N., & Kanai∥, T. (2022) · Seminars in Liver Disease · doi:10.1055/a-1957-6384 · Cited by 19

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis

Magee, N. S., Ahamed, F., Eppler, N., Jones, E., Ghosh, P., He, L., & Zhang, Y. (2022) · Liver Research · doi:10.1016/j.livres.2022.11.001 · Cited by 20

The tetraspanin transmembrane protein CD53 mediates dyslipidemia and integrates inflammatory and metabolic signaling in hepatocytes

Higgins, C. B., Adams, J. A., Ward, M. H., Greenberg, Z. J., Milewska, M., Sun, J., Zhang, Y., Paracatu, L. C., Dong, Q., Ballentine, S. J., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102835 · Cited by 19

Mechanism of immune attack in the progression of obesity-related type 2 diabetes

Wang, H., Tang, J., Sun, L., Li, Z., Deng, M., & Dai, Z. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.494 · Cited by 22

Role of extracellular vesicles in nonalcoholic fatty liver disease

Jiang, W., Xu, Y., Chen, J.-C., Lee, Y.-H., Hu, Y., Liu, C., Chen, E., Tang, H., Zhang, H., & Wu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1196831 · Cited by 20

N6-methyladenosine RNA modification in nonalcoholic fatty liver disease

Ping, L., Li, S., Wei, J., Tu, J., & Long, X. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.09.002 · Cited by 20

Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity

Tzeng, H., & Lee, W.-C. (2024) · Nutrients · doi:10.3390/nu16091388 · Cited by 18

Therapeutic Targets and Approaches to Manage Inflammation of NAFLD

Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20

Role of regulatory T cells in inflammatory liver diseases

Yang, L., & Zheng, S. G. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103806 · Cited by 17

Oral exposure to PLA microplastics induces time-dependent nanotoxicity via the gut-liver axis

Fan, J., Qu, Y., Qu, L., Shen, D., Liu, H., & Nie, Z. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138931 · Cited by 21

Possible Gender Influence in the Mechanisms Underlying the Oxidative Stress, Inflammatory Response, and the Metabolic Alterations in Patients with Obesity and/or Type 2 Diabetes

Contreras-Zentella, M. L., & Hernández-Muñoz, R. E. (2021) · Antioxidants · doi:10.3390/antiox10111729 · Cited by 19

Targeted inhibition of the immunoproteasome blocks endothelial MHC class II antigen presentation to CD4+ T cells in chronic liver injury

Zhang, Y., Yang, X., Bi, T., Wu, X., Wang, L., Ren, Y., Ou, Y., Xie, C., Li, K., Ran, H., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108639 · Cited by 18

Single-cell RNA sequencing reveals a novel inhibitory effect of ApoA4 on NAFL mediated by liver-specific subsets of myeloid cells

Liu, X.-H., Zhou, J., Yan, C., Cheng, C., Fan, J., Xu, J., Zheng, Q., Baï, Q., Li, Z., Li, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038401 · Cited by 17

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease

Waller, K., Saihi, H., Li, W., Brindley, J. H., Jong, A. D., Syn, W., Bessant, C., & Alazawi, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0205 · Cited by 18

A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis

Li, X., Lu, Y., Liang, X., Zhou, X., Li, D., Zhang, Z., Niu, Y., Liu, S., Ye, L., & Zhang, R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286257 · Cited by 17

State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy

Zhong, X., Lv, M., Ma, M., Huang, Q., Hu, R., Li, J., Yi, J., Sun, J., & Zhou, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115131 · Cited by 20

The multifaceted roles of B lymphocytes in metabolic dysfunction–associated steatotic liver disease

Li, H., & Xia, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447391 · Cited by 23

Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease

Jin, L.-T., & Xu, M.-Z. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1113643 · Cited by 18

Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies

Raza, S., Mahamood, R., Medhe, P., Shahi, A., Yadav, A., Tewari, A., & Sinha, R. A. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00083-0 · Cited by 21

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

Galatou, E., Mourelatou, E. A., Hatziantoniou, S., & Vizirianakis, I. S. (2022) · Antioxidants · doi:10.3390/antiox11061060 · Cited by 18

Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease

Liu, X., Jiang, Y., Ye, J., & Wang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999412 · Cited by 18

Preventive and therapeutic effects of natural products and herbal extracts on nonalcoholic fatty liver disease / nonalcoholic steatohepatitis

Cao, Y., Fang, X., Sun, M., Zhang, Y., Shan, M., Lan, X., Zhu, D., & Luo, H. (2023) · Phytotherapy Research · doi:10.1002/ptr.7932 · Cited by 17

Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: A systematic review

Ng, J. J. J., Loo, W. M., & Siah, K. T. H. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i7.925 · Cited by 19

Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)

Singh, S., Kumar, A., Gupta, S., & Agrawal, R. (2023) · Tissue Barriers · doi:10.1080/21688370.2023.2289830 · Cited by 17

Diagnostic Challenges during Inflammation and Cancer: Current Biomarkers and Future Perspectives in Navigating through the Minefield of Reactive versus Dysplastic and Cancerous Lesions in the Digestive System

Pateras, I. S., Igea, A., Nikas, I. P., Leventakou, D., Koufopoulos, N. I., Ieronimaki, A. I., Bergonzini, A., Ryu, H. S., Chatzigeorgiou, A., Frisan, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021251 · Cited by 17

Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

Purssell, H., Whorwell, P. J., Athwal, V. S., & Vasant, D. H. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.1816 · Cited by 20

Mechanisms of Metal-Induced Hepatic Inflammation

Subramaniam, N., & Mann, K. K. (2024) · Current Environmental Health Reports · doi:10.1007/s40572-024-00463-6 · Cited by 18

The Impact of Inflammatory Immune Reactions of the Vascular Niche on Organ Fibrosis

Zhou, H., Sui, H. X., Zhao, Y.-J., Qian, H.-J., Yang, N., Liu, L., Guan, Q., Zhou, Y., Lin, H., & Wang, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750509 · Cited by 15

Mouse promyelocytic leukemia zinc finger protein (PLZF) regulates hepatic lipid and glucose homeostasis dependent on SIRT1

Hu, H., Sun, N., Du, H., He, Y., Pan, K., Liu, X., Lu, X.-X., Wei, J., Liao, M.-M., & Duan, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1039726 · Cited by 16

Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease

van Son, K. C., Verschuren, L., Hanemaaijer, R., Reeves, H. L., Takkenberg, R. B., Drenth, J. P. H., Tushuizen, M. E., & Holleboom, A. G. (2023) · Cancers · doi:10.3390/cancers15041308 · Cited by 17

Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease

Li, Z., Ouyang, H., & Zhu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1195146 · Cited by 16

Sterile inflammation in liver transplantation

Kahan, R., Cray, P. L., Abraham, N., Gao, Q., Hartwig, M. G., Pollara, J., & Barbas, A. S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1223224 · Cited by 16

Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

Zhang, M., Barroso, E., Ruart, M., Peña, L., Peyman, M., Aguilar-Recarte, D., Montori-Grau, M., Rada, P., Cugat, C., Montironi, C., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115623 · Cited by 16

The PD-1/PD-L1 Axis in the Biology of MASLD

Pipitone, R. M., Lupo, G., Zito, R., Javed, A., Petta, S., Pennisi, G., & Grimaudo, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073671 · Cited by 20

A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis

Park, J.-S., Lee, J., Wang, F., Ma, H., Zhou, Z., Lee, Y.-S., Oh, K., Lee, H., Sui, G., Lee, S., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01408-1 · Cited by 15

The effect of liver disease on hepatic microenvironment and implications for immune therapy

Brown, Z. J., Ruff, S. M., & Pawlik, T. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1225821 · Cited by 18

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches

Arvanitakis, K., Papadakos, S. P., Lekakis, V., Koufakis, T., Lempesis, I. G., Papantoniou, E., Kalopitas, G., Georgakopoulou, V., Stergiou, I. Ε., Theocharis, S. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914704 · Cited by 16

Identification and validation of INHBE and P4HA1 as hub genes in non-alcoholic fatty liver disease

Cao, J., Zhong, Q., Huang, Y., Zhu, M., Wang, Z., & Xiong, Z. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149180 · Cited by 15

Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice

Opazo-Ríos, L., Soto‐Catalán, M., Lázaro, I., Sala‐Vila, A., Jiménez-Castilla, L., Orejudo, M., Moreno, J. A., Egido, J., & Mas, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073965 · Cited by 15

Diet Containing Soy Protein Concentrate With Low and High Isoflavones for 9 Weeks Protects Against Non-alcoholic Fatty Liver Steatosis Using Obese Zucker Rats

Hakkak, R., Spray, B. J., Børsheim, E., & Korourian, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.913571 · Cited by 15

Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice

Tao, S.-H., Lei, Y., Tan, Y., Yang, Y.-B., & Xie, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1476419 · Cited by 16

Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility

Lou, C., Lan, T., Xu, S., Hu, X., Li, J., Xiang, Z., Lin, S., Fan, X., Chen, J., & Xu, X. (2025) · Gut · doi:10.1136/gutjnl-2025-334763 · Cited by 15

Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma

Zarlashat, Y., Ghaffar, A., Guerra, F., & Picca, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167836 · Cited by 17

Cyclo(His-Pro): A further step in the management of steatohepatitis

Masi, A. D., Li, X., Lee, D., Jeon, J., Wang, Q., Baek, S., Park, O., Mottis, A., Strotjohann, K., Rapin, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100815 · Cited by 14

Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease

Liu, J., Li, Y., Ma, J., Wan, X., Zhao, M., Zhang, Y., & Shang, D. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01878-0 · Cited by 14

Disruption of cholangiocyte-B cell crosstalk by blocking the CXCL12-CXCR4 axis alleviates liver fibrosis

Zhang, L., Zhao, C., Dai, W., Tong, H., Yang, W., Huang, Z., Tang, C., & Gao, J. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05032-y · Cited by 14

Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B

Osmani, Z., Brouwer, W. P., Grashof, D. G. B., Lim, Y., Doukas, M., Janssen, H. L. A., van de Werken, H. J. G., & Boonstra, A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.032 · Cited by 14

Immune Checkpoints and the Immunology of Liver Fibrosis

Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 14

The combination of experimental periodontitis and oral microbiota from periodontitis patients aggravates liver fibrosis in mice

Bai, L., Wang, Y., Chen, Y., Li, H., Zhu, S., Liu, Y., Song, Z., & Duan, S. (2022) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13682 · Cited by 14

Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease

Yi, S., Cong, Q., Zhu, Y., & Xu, Q. (2023) · Stem Cells International · doi:10.1155/2023/3919002 · Cited by 15

PRDX6 Promotes Fatty Acid Oxidation via PLA2-Dependent PPARα Activation in Rats Fed High-Fat Diet

Shen, W., Yang, L. S., Yang, Y., Wang, P., Tao, X., Shen, Y., Wang, S., & Shen, Y. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0065 · Cited by 13

Healthy diet intervention reverses the progression of NASH through gut microbiota modulation

Panyod, S., Wu, W., Hu, M.-Y., Huang, H., Chen, R.-A., Chen, Y., Shen, T. D., Ho, C., Liu, C., Chuang, H.-L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01868-23 · Cited by 14

The double roles of T cell-mediated immune response in the progression of MASLD

Li, Z., Wang, S., Xu, Q., Su, X., Wang, Y., Wang, L., & Zhang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116333 · Cited by 15

Oral Health and “Modern” Digestive Diseases: Pathophysiologic and Etiologic Factors

Rotaru, M., Sîngeap, A.-M., Ciobica, A. S., Huiban, L., Stanciu, C., Romila, L. E., Burlui, V., Mavroudis, I. A., & Trifan, A. V. (2024) · Biomedicines · doi:10.3390/biomedicines12081854 · Cited by 16

Identification of ribosomal protein family as immune-cell-related biomarkers of NAFLD by bioinformatics and experimental analyses

Li, G., Li, H., & Chen, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161269 · Cited by 13

Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in Mice

de Assis, L. V. M., Demir, M., & Oster, H. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.05.008 · Cited by 13

Mouse models of nonalcoholic steatohepatitis and their application to new drug development

Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13

Dynamic crosstalk between HSCs and liver microenvironment: multicellular interactions in the regulation of liver fibrosis

Wang, L., Huang, Y., Chen, J., Gao, J., Chen, S., Zhao, M., Lin, J., Zhou, S., Shen, Y., & Cheng, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1635763 · Cited by 15

Tyrosol attenuates NASH features by reprogramming the hepatic immune milieu

Gabbia, D., Sayaf, K., Zanotto, I., Colognesi, M., Frión-Herrera, Y., Carrara, M., Russo, F. P., & Martin, S. D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176453 · Cited by 12

Deciphering the Effective Constituents and Mechanisms of Portulaca oleracea L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology

He, X., Hu, Y., Liu, W., Zhu, G., Zhang, R., You, J., Shao, Y., Li, Y., Zhang, Z., Cui, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.818227 · Cited by 12

Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease

Sabotta, C. M., Kwan, S., Petty, L. E., Below, J. E., Joon, A. Y., Wei, P., Fisher‐Hoch, S. P., McCormick, J. B., & Beretta, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.995488 · Cited by 12

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

Che, W., Zhao, M., Li, X., Li, C., Cho, W. C. S., & Yu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002916 · Cited by 12

Enhanced inflammasome-mediated inflammation and impaired autophagy in peripheral blood mononuclear cells is associated with non-alcoholic fatty liver disease severity

Saha, S., Ray, S., Mandal, A., Das, U. B., Bhattacharya, T., Shireen, Z., Sarkar, S., Sharma, R. D., Ghosh, S., & Dey, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121911 · Cited by 12

Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity

Lamadrid, P., Alonso‐Peña, M., Segundo, D. S., Arias, M., Crespo, J., & López‐Hoyos, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651728 · Cited by 12

Is there a role for adaptive immunity in nonalcoholic steatohepatitis?

Sutti, S., Jindal, A., Bruzzì, S., Locatelli, I., Bozzola, C., & Albano, E. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i13.1725 · Cited by 14

Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression

Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A. D., Loguercio, C., Serviddio, G., & Federico, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010436 · Cited by 77

Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma

Peiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 77

Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease

Trejo, A. M. C., Větvička, V., Vištějnová, L., Králíčková, M., & Montúfar, E. B. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1887730 · Cited by 41

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)

Nati, M., Haddad, D., Birkenfeld, A. L., Koch, C. A., Chavakis, T., & Chatzigeorgiou, A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9339-2 · Cited by 138